Spitalul Clinic Judetean De Urgenta Pius Brinzeu
- Address
- lock Available on a paid plan
Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara - Emergency and Multi-Specialty Research Center
Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara is a prominent emergency clinical hospital in Romania with significant expertise in conducting advanced clinical research across multiple therapeutic areas. The center demonstrates particular strength in neurological disorders, acute cardiovascular conditions, and infectious disease management, with a focus on emergency and critical care interventions.
- Neurological conditions including multiple sclerosis and acute cerebrovascular events such as ischemic stroke and transient ischemic attacks
- Severe respiratory infections, specifically community-acquired pneumonia and bacterial pneumonia requiring intensive care
- Cardiovascular disease prevention and anticoagulation management in high-risk surgical populations
- Infectious diseases including complicated urinary tract infections, acute pyelonephritis, and chronic hepatitis D infection
The research center participates in international Phase 2 and Phase 3 clinical trials evaluating both novel therapeutic agents and established treatments in emergency settings. Their clinical trial portfolio reflects their capabilities in managing acute care scenarios, including urgent surgical anticoagulation reversal, severe pneumonia treatment protocols, and cardiovascular risk reduction strategies. The facility's involvement in long-term safety studies and registry-based research demonstrates commitment to comprehensive patient care and advancing medical knowledge in critical care medicine and emergency therapeutics.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 11 therapeutic areas and 15 of 73 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 59 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 19 by active trials.
- 1Novo Nordisk A/S2active
lock +18 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S5trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Spitalul Clinic Judetean De Urgenta Pius Brinzeu
lock Showing 1 of 42 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults with Moderate or Severe Diabetic Foot Infections | Micurx Pharmaceuticals Inc. | Phase III | Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 73 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Batoclimab | 3 | Unknown | 2023-02-03 | 2025-05-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.